• Institute Professor from MIT
• Chairman of the Scientific Advisory Board
• Member of National Academy of Engineering
• American Academy of Arts and Sciences, and Academia Sinica
Dr. Daniel I.C. Wang is an Institute Professor (MIT Highest Honor) at Massachusetts Institute of Technology. He is a member of National Academy of Engineering, American Academy of Arts and Sciences, and Academia Sinica. He was the editor-in-chief for Biotechnology and Bioengineering for more than 10 years. Over 40 years of pioneering and innovative research in the field of biotechnology and biochemical engineering, Prof. Wang has made profound impact on the biotechnology industry scientific research, and education.
Lots of his students have become main technical backbone and senior leadership in the biotechnology and pharmaceutical companies of United States and Europe. His research interests and contribution to the biotech industry include mammalian cell culture, microbial fermentation, protein purification and refolding, bioreactor engineering, production of recombinant proteins, bioprocess monitoring and control, glycoprotein quality, protein stabilization, enzyme technology and cellulosic biomass conversion.
Professor Wang is a patriotic Chinese American, who has been concerned about the development of biotechnology in China, and trained a number of PhDs and senior visiting scholars for China. He served as foreign experts and consultants for Ministry of Science and Technology (China) in the 1980s. He is also engaged as biotechnology strategy consultant of Singapore, and has made important contributions to the development of biotechnology in Singapore.Prof. Wang also received Honorary Professorships from Peking Union Medical College, China, and Zhejiang University, China.
Dr. Xie founded Sino Biological Inc. in 2007 and served as the President and CEO form 2007 to 2018. He started the business for producing research reagents and providing CRO services to global pharmaceutical companies.
Dr. Xie began his career as a research fellow at Merck & Company. He has extensive experience in viral vaccine development. He worked on viral vaccine process development and cGMP manufacturing for three US FDA approved products (Varicella®, Zostervax®, and ProQuad®). He also led the cell culture and viral vaccine process development and cGMP clinical production for Merck's adenovirus based HIV vaccine and helped to develop by far the largest scale (2000L) of human viral vaccine process under serum-free condition in stirred-tank bioreactors.Dr. Xie obtained his doctor degree from the biotechnology process engineering center at Massachusetts Institute of Technology under the supervision of Prof. Daniel I.C. Wang.
• Vice president of Sino Biological Inc.
• Director of Beijing Key Laboratory of Upstream Research and Development Technology for Monoclonal Antibodies
Jie Zhang graduated from Beijing Medical Sciences University in 1997 with a bachelor's degree in clinical medicine. In 2002, he obtained a doctorate from the Peking University Health Science Center. In 2003, he went to the United States and was mainly engaged in immunology research at the Dr. Diamond's Laboratory who is the academician of American Academy of Medical Sciences at Einstein College of Medicine and Columbia University. After returning to China in 2009, Dr. Zhang Jie was responsible for product research and development and has successfully developed more than 9,000 antibodies and more than 500 kits. He also has led the development of upstream research and development and downstream quality control methodologies for multiple protein, antibody and vaccine drug candidates.
2018-Now, he served as vice president of Sino Biological Inc.